Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Bridges

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
ACS Chemical Neuroscience|June 16, 2025
Correction to "Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool Compound"Kentaro Yashiro, Yuzo Iwaki, Hirohito Urata, et al.
ACS Chemical Neuroscience|February 21, 2025
Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool CompoundKentaro Yashiro, Yuzo Iwaki, Hirohito Urata, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Investigative Ophthalmology & Visual Science|January 26, 2018
Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for RetinoblastomaAnthony B Daniels, Michael T Froehler, Janene M Pierce, et al.
Bioorganic & Medicinal Chemistry Letters|December 1, 2019
Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotypeKayla J Temple, Julie L Engers, Madeline F Long, et al.
Human Molecular Genetics|March 4, 2016
mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeRocco G Gogliotti, Rebecca K Senter, Jerri M Rook, et al.
Neuropharmacology|July 22, 2017
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M<sub>4</sub> PAM VU0467154Robert W Gould, Michael D Grannan, Barak W Gunter, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
ACS Chemical Neuroscience|June 16, 2025
Correction to "Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool Compound"Kentaro Yashiro, Yuzo Iwaki, Hirohito Urata, et al.
ACS Chemical Neuroscience|February 21, 2025
Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool CompoundKentaro Yashiro, Yuzo Iwaki, Hirohito Urata, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Investigative Ophthalmology & Visual Science|January 26, 2018
Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for RetinoblastomaAnthony B Daniels, Michael T Froehler, Janene M Pierce, et al.
Bioorganic & Medicinal Chemistry Letters|December 1, 2019
Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotypeKayla J Temple, Julie L Engers, Madeline F Long, et al.
Human Molecular Genetics|March 4, 2016
mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeRocco G Gogliotti, Rebecca K Senter, Jerri M Rook, et al.
Neuropharmacology|July 22, 2017
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M<sub>4</sub> PAM VU0467154Robert W Gould, Michael D Grannan, Barak W Gunter, et al.
Pageof 11